AHP diet drug settlement
The $4.75 bil. allocated for the Redux and Pondimin diet drug settlement "remains adequate," American Home Products said April 13 with news that less than 1% of those covered by the nationwide class action litigation opted out of the settlement. "Although a final report has not yet been submitted...approximately 200,000 individuals have registered for the settlement to date and approximately 45,000 opted out during the four month opt-out period that ended on March 30," the company said
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth